ALDUET Montelukast Sodium / Cetirizine Hydrochloride 10mg / 10mg Film-Coated Tablet 1's
RXDRUG-DR-XY43106-1pc
Discreet Packaging
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
FDA-registered Products
FDA-licensed Pharmacies
Features
Brand
Alduet
Full Details
Dosage Strength
10mg / 10mg
Drug Ingredients
- Cetirizine
- Montelukast
Drug Packaging
Film-Coated Tablet 1's
Generic Name
Montelukast Sodium / Cetirizine Hcl
Dosage Form
Film-Coated Tablet
Registration Number
DR-XY43106
Drug Classification
Prescription Drug (RX)
Description
Indications/Uses
For the relief of symptoms associated with seasonal and perennial allergic rhinitis, and chronic urticaria.
Dosage/Direction for Use
Adult and Children > 12 years old: One tablet containing 10 mg Montelukast + 10 mg Cetirizine once daily or as prescribed by the physician.
Elderly: At present there are no data to suggest that the dose need to be reduced in elderly patients.
Patients with Hepatic and Renal Impairment: Dosage should be reduced to half the usual daily dose in patients with hepatic or renal impairment.
Elderly: At present there are no data to suggest that the dose need to be reduced in elderly patients.
Patients with Hepatic and Renal Impairment: Dosage should be reduced to half the usual daily dose in patients with hepatic or renal impairment.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Severe renal (CrCl <10 mL/min) or hepatic impairment. Pregnancy & lactation. Childn 6-11 yr w/ renal impairment.
MONTELUKAST + CETIRIZINE is contraindicated in patients with a known hypersensitivity to Montelukast or Cetirizine, patients with severe renal (creatinine clearance less than 10 mL/min) or hepatic impairment, in children 6-11 years of age with renal impairment, and during women who are pregnant or breastfeeding.
Special Precautions
Cetirizine: Reduce dose in patients w/ hepatic or renal impairment.
Cetirizine: Reduced dosage is recommended for patients with hepatic or renal impairment.
Effects on the Ability to Drive or Operate Machinery: Studies in healthy volunteers at 20 and 25mg/day have not revealed effects on alertness or reaction time; however, patients are advised not to exceed the recommended dose if driving or operating machinery.
Effects on the Ability to Drive or Operate Machinery: Studies in healthy volunteers at 20 and 25mg/day have not revealed effects on alertness or reaction time; however, patients are advised not to exceed the recommended dose if driving or operating machinery.
Use In Pregnancy & Lactation
No well controlled trials have been performed with either Montelukast or Cetirizine in women who are pregnant. Therefore use of MONTELUKAST + CETIRIZINE is not recommended in women who are pregnant. It is not known whether Montelukast or Cetirizine is excreted in breast milk. Therefore use of MONTELUKAST + CETIRIZINE is not recommended in women who are breast feeding.
Adverse Reactions
Montelukast: Asthenia/fatigue, fever, abdominal pain, trauma; dyspepsia, infectious gastroenteritis, dental pain; dizziness, headache; nasal congestion, cough, flu; rash; increased ALT or AST, pyuria. Cetirizine: Drowsiness, agitation, dry mouth, GI discomfort, arrhythmia. Sedation; hypersensitivity reactions (urticaria), fixed drug eruptions.
Montelukast has been evaluated for safety in approximately 2950 adult and adolescent patients 15 years of age and older in clinical trials. In placebo-controlled clinical trials, the following adverse experiences reported with montelukast (M) occurred in greater than or equal to 1% of patients and at an incidence greater than that in patients treated with placebo (P), regardless of causality assessment.
Body As A Whole: Asthenia/fatigue M (1.8%), P (1.2%). Fever: M (0.6%), P (3.0%). Abdominal Pain: M (2.9%), P (2.5%) Trauma: M (1.0%), P (0.8%).
Digestive System Disorders: Dyspepsia M (2.1%), P (1.1%). Infectious gastroenteritis: M (2.1%), P (1.1%). Dental Pain: M (1.7%), P (1.0%).
Nervous System/Psychiatric: Dizziness M (1.9%), P (1.4%). Headache: M (18.4%), P (18.1%).
Respiratory System Disorders: Congestion, nasal M (1.6%), P (1.3%). Cough M (2.7%), P (2.4%). Influenza: M (4.2%), P (3.9%).
Skin/Skin Appendages Disorder: Rash M (1.6%), P (1.2%).
Laboratory Adverse Experiences:* ALT increased M (2.1%), P (2.0%). AST increased M (1.6%), P (1.2%). Pyuria: M (1.0%), P (0.9%).
Cetirizine: There have been occasional reports of mild and transient subjective side effects e.g., headache, dizziness, drowsiness, agitation, dry mouth and gastrointestinal discomfort.
Arrhythmias: The ECG effects of Cetirizine when administered a dose of up to six times the usual recommended dose did not prolong the QT interval.
Hypersensitivity: Hypersensitivity reactions manifest as urticaria and fixed drug eruptions have been reported with Cetirizine.
Sedation: CNS depression is the most common adverse effect of Cetirizine. The sedative effect can range from slight drowsiness to deep sleep.
Body As A Whole: Asthenia/fatigue M (1.8%), P (1.2%). Fever: M (0.6%), P (3.0%). Abdominal Pain: M (2.9%), P (2.5%) Trauma: M (1.0%), P (0.8%).
Digestive System Disorders: Dyspepsia M (2.1%), P (1.1%). Infectious gastroenteritis: M (2.1%), P (1.1%). Dental Pain: M (1.7%), P (1.0%).
Nervous System/Psychiatric: Dizziness M (1.9%), P (1.4%). Headache: M (18.4%), P (18.1%).
Respiratory System Disorders: Congestion, nasal M (1.6%), P (1.3%). Cough M (2.7%), P (2.4%). Influenza: M (4.2%), P (3.9%).
Skin/Skin Appendages Disorder: Rash M (1.6%), P (1.2%).
Laboratory Adverse Experiences:* ALT increased M (2.1%), P (2.0%). AST increased M (1.6%), P (1.2%). Pyuria: M (1.0%), P (0.9%).
Cetirizine: There have been occasional reports of mild and transient subjective side effects e.g., headache, dizziness, drowsiness, agitation, dry mouth and gastrointestinal discomfort.
Arrhythmias: The ECG effects of Cetirizine when administered a dose of up to six times the usual recommended dose did not prolong the QT interval.
Hypersensitivity: Hypersensitivity reactions manifest as urticaria and fixed drug eruptions have been reported with Cetirizine.
Sedation: CNS depression is the most common adverse effect of Cetirizine. The sedative effect can range from slight drowsiness to deep sleep.
Drug Interactions
Montelukast: Decreased AUC w/ phenobarb. CYP3A4 inducers eg, phenytoin, rifampicin (particularly in childn). Cetirizine: Increased serum conc w/ pilsicainide. Increased INR & severe epistaxis w/ long-term acenocoumarol.
In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/ norethindrone 35/1), terfenadine, digoxin and warfarin. The area under the plasma concentration curve (AUC) for Montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since Montelukast is metabolised by CYP 3A4, caution should be exercised, particularly in children, when Montelukast is coadministered with inducers of CYP 3A4, such as phenytoin, phenobarbital and rifampicin. In vitro studies have shown that Montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving Montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP 2C8) demonstrated that Montelukast does not inhibit CYP 2C8 in vivo. Therefore, Montelukast is not anticipated to markedly alter the metabolism of drugs metabolized by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide).
Cetirizine: Some interactions are less likely with Cetirizine than with non-sedating antihistamines such as astemizole and terfenadine, since Cetirizine appears to have low hepatic metabolism and little arrhythmogenic potential.
Concomitant use of Cetirizine and pilsicainide may increase the serum concentration of both drugs which may lead to drug toxicities.
Anticoagulants: There has been a report of a raised INR and severe epistaxis in a patient after the addition of Cetirizine to long-term acenocoumarol.
Cetirizine: Some interactions are less likely with Cetirizine than with non-sedating antihistamines such as astemizole and terfenadine, since Cetirizine appears to have low hepatic metabolism and little arrhythmogenic potential.
Concomitant use of Cetirizine and pilsicainide may increase the serum concentration of both drugs which may lead to drug toxicities.
Anticoagulants: There has been a report of a raised INR and severe epistaxis in a patient after the addition of Cetirizine to long-term acenocoumarol.
Storage
Store at temperatures not exceeding 30°C. conditions for details to ensure optimal shelf-life.
Action
Alduet mechanism of action for pharmacodynamics and pharmacokinetics details.
Montelukast: The cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important mediators bind to cysteinyl leukotriene receptors. Cysteinyl leukotrienes have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment. In allergic rhinitis, cysteinyl leukotrienes are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis. Intranasal challenge with cysteinyl leukotrienes has been shown to increase nasal airway resistance and symptoms of nasal obstruction. Montelukast is an orally active compound which binds with high affinity and selectivity to the cysteinyl leukotriene type 1 receptor thereby preventing cysteinyl leukotrienes from exerting their effects.
Cetirizine: Cetirizine hydrochloride, a piperazine derivative and metabolite of hydroxyzine, is described as a non-sedating antihistamine which is long-acting and has some mast-cell stabilizing activity. It appears to have a low potential for drowsiness in usual doses and to be virtually free of antimuscarinic activity. It is a selective H1-antagonist with negligible effects on other receptors and so it is virtually free from anticholinergic and antiserotonin effects. Cetirizine inhibits the histamine-mediated "early" phase of the allergic reaction and also reduces the migration of inflammatory cells e.g., eosinophils and the release of mediators associated with the "late" allergic response.
Pharmacokinetics: Montelukast: Absorption: Montelukast is rapidly absorbed 2 to 4 hours following oral administration. Mean peak plasma concentration (Cmax) is achieved 3 hours (Tmax) after administration of a 10 mg dose in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and Cmax are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10-mg film-coated tablet was administered without regard to the timing of food ingestion. Cmax is achieved in 2 hours after administration of the 5 mg chewable tablet in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.
Cetirizine: Cetirizine hydrochloride, a piperazine derivative and metabolite of hydroxyzine, is described as a non-sedating antihistamine which is long-acting and has some mast-cell stabilizing activity. It appears to have a low potential for drowsiness in usual doses and to be virtually free of antimuscarinic activity. It is a selective H1-antagonist with negligible effects on other receptors and so it is virtually free from anticholinergic and antiserotonin effects. Cetirizine inhibits the histamine-mediated "early" phase of the allergic reaction and also reduces the migration of inflammatory cells e.g., eosinophils and the release of mediators associated with the "late" allergic response.
Pharmacokinetics: Montelukast: Absorption: Montelukast is rapidly absorbed 2 to 4 hours following oral administration. Mean peak plasma concentration (Cmax) is achieved 3 hours (Tmax) after administration of a 10 mg dose in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and Cmax are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10-mg film-coated tablet was administered without regard to the timing of food ingestion. Cmax is achieved in 2 hours after administration of the 5 mg chewable tablet in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.
MedsGo Class
Antihistamines & Antiallergics
Please sign in so that we can notify you about a reply